Biopharma Services

1. Cell line identification (using sanger sequencing)
2. Microbial identification (MID)
3. Pharmacogenomics

a. Whole genome sequencing of genome
b. Exome sequencing of Human genome
c. Targeted SNP sequencing using ABI3730xl sanger sequencing
d. SNP association tested for Drug response
e. Identify SNP biomarkers associated with the disease and correlate with phenotype (All animal models, human)

4. Microbial cell bank testing service

1. Mapping on the reference / insert sequence
2. Flanking sequence identification (using NGS or Sanger primer walking)
3. Identification of variation
4. Comparison between master and working cell bank

5. RNA-Seq for Clinical Trials

a. Assess drug treatment
b. Identify gene targets by RNA-Seq analysis

6. Verify working and master seed stock testing at genomics level

To demonstrate the stability of the genotype following passages beyond the level used in the production. Genotypic characterization of a viral seed includes its sequence, may also include analysis of viral subpopulations and its genetic stability. This can be achieved through the following services:

1. Whole Genome Sequencing

a. Whole genome sequence
b. SNP Discovery and annotation
c. Comparison of the genomics sequence of Master and Working sequence.
d. Insert characterization of biologic genes

2. Identification of adventitious agents
a. 16S/ITS analysis
b. Shotgun Metagenomics

7. Drug discovery

NGS has a central role in the discovery of new genomic biomarkers, detection of mutations, personalized medicine and pharmacogenetics, target identification and validation, clinical diagnostics, vaccine development, investigating drug resistance and many others. This can be achieved through the following services: